,
,
,
,
Quels traitements de la maladie de Parkinson à l'heure actuelle ? ,
,
,
, Quatrième partie : Maladies neurodégénératives, les opportunités de demain
,
,
,
75 1. Traitements de fonds basés sur l'utilisation de principes actifs chimiques ,
, Chapitre II : Les axes de recherche pour le traitement des maladies neurodégénératives, p.78
,
,
,
,
,
, , vol.87
,
Alzheimer's discovery. Current Biology, vol.16, pp.906-916, 2006. ,
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun. 16 mai, vol.120, issue.3, pp.885-90, 1984. ,
Neurofibrillary tangles and Alzheimer's disease, Eur Neurol. oct, vol.40, issue.3, pp.130-170, 1998. ,
Alzheimer's Disease: Pathology and Pathogenesis, Reference Module in Biomedical Sciences, 2014. ,
,
, Gérontologie et société. 1 sept, vol.32, issue.1, pp.129-170, 2009.
The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. Cold Spring Harb Perspect Med, 2011. ,
, Parkinson's disease. The Lancet, août, vol.29, issue.1, pp.896-912, 2015.
Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects ,
Parkinsonism: onset, progression and mortality ,
, Disponible sur: /paper/Parkinsonism%3A-onset%2C-progression-and-mortality
Neuropathology of Parkinson disease, Parkinsonism & Related Disorders. 1 janv, vol.46, pp.30-33, 2018. ,
Structural and functional characterization of two alpha-synuclein strains, Nature Communications, vol.4, p.2575, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01183047
UK Parkinson's Disease Society Brain Bank Diagnostic Criteria ,
,
Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management. Cold Spring Harbor perspectives in medicine, 1 juin, vol.2, p.8870, 2012. ,
The diagnosis of Parkinson's disease, The Lancet Neurology. 1 janv, vol.5, issue.1, pp.75-86, 2006. ,
, Haute Autorité de Santé -Guide parcours de soins maladie de Parkinson
What are Common Risk Factors for Parkinson's? ,
,
,
Pharma industry research and analysis, patient forecasts, epidemiology and key event insights | Datamonitor Healthcare, PET Clinics, vol.8, issue.4, pp.447-58, 2013. ,
,
World Health Organization ,
, Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study, The Lancet Neurology, vol.16, issue.11, pp.877-97, 2015.
Impact socio-économique de la maladie d'Alzheimer et des maladies apparentées en Europe, socio-economic impact of alzheimer type diseases in europe, Gérontologie et société. 1 sept, vol.32, issue.1, pp.297-318, 2009. ,
Alzheimer en chiffres ,
,
Carcaillon-Bentata L. Épidémiologie de la maladie de Parkinson, données nationales / Epidemiology of Parkinson's disease, French national data, Neurology. mars, vol.43, issue.3, pp.515-524, 1993. ,
,
,
, The Global Impact of Dementia, 2015.
,
Combien coûte la maladie d'Alzheimer ?, vol.100, 2015. ,
Alzheimer : 900 000 malades, 2 millions d'aidants, 19 milliards d'euros de coûts? et 0 traitement. Le Monde.fr [Internet]. 21 sept, 2016. ,
Economic Burden Associated With Parkinson Disease | Patient Care ,
, The Cost of Parkinson's disease
, , 2014.
Cost of disorders of the brain in Europe, Eur Neuropsychopharmacol, vol.21, issue.10, pp.718-79, 2010. ,
Chapter Thirteen -Treatment of Alzheimer's Disease. In: Brewer GJ, éditeur. Environmental Causes and Prevention Measures for Alzheimer's Disease, 2018. ,
, Capsule outil : Alzheimer : perspectives de traitements, pp.119-145
Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease, Drug Des Devel Ther. 6 févr, vol.2, pp.245-54, 2009. ,
An update on the pharmacology of galantamine, REMINYL et génériques (bromhydrate de galantamine) : risque de réactions cutanées graves, vol.16, 2007. ,
,
Complementary Mechanisms in the Treatment of Alzheimer's Disease, Neurotox Res, vol.24, issue.3, pp.358-69, 2013. ,
Cognitive intervention in Alzheimer disease, Nature Reviews Neurology. sept, vol.6, issue.9, pp.508-525, 2010. ,
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease, 2018. ,
Physical Exercise as a Preventive or Disease-Modifying Treatment of Dementia and Brain Aging, Mayo Clinic Proceedings. 1 sept, vol.86, issue.9, pp.876-84, 2011. ,
The Effect of Music Participation on the Social Behavior of Alzheimer's Disease Patients, J Music Ther. 1 mars, vol.29, issue.1, pp.54-67, 1992. ,
Functional alterations in memory networks in early Alzheimer's disease, Brain Stimulation for Combating Alzheimer's Disease. Front Neurol, vol.12, pp.27-43, 2010. ,
Benefits of Deep Transcranial Magnetic Stimulation in Alzheimer Disease: Case Series, J ECT. juin, vol.32, issue.2, pp.127-160, 2016. ,
Current approaches to the treatment of Parkinson's Disease ,
, Bioorg Med Chem Lett, vol.15, issue.18, pp.4247-55, 2017.
, Comment évolue le traitement de la maladie de Parkinson ? -EurekaSanté par VIDAL
, , 2018.
,
, Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, Eur J Neurol. févr, vol.21, issue.2, pp.312-320, 2014.
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease, J Clin Pharmacol. août, vol.45, issue.8, pp.878-94, 2005. ,
My 25 Stimulating Years with DBS in Parkinson's Disease, J Parkinsons Dis, issue.7, pp.35-43 ,
Neurostimulation Devices for the Treatment of Neurologic Disorders, Mayo Clinic Proceedings. 1 sept, vol.92, issue.9, pp.1427-1471, 2017. ,
Chapter 6 -Parkinson's disease, Baekelandt V, Lobbestael E, éditeurs. Disease-Modifying Targets in Neurodegenerative Disorders [Internet, 2017. ,
,
, Market Research Reports
Retrospective Evaluation of Deep Transcranial Magnetic Stimulation as Add-On Treatment for, Parkinson's Disease. Front Neurol, vol.6, p.210, 2015. ,
Nonpharmacological treatments for patients with Parkinson's disease. Movement Disorders. 15 sept, vol.30, pp.1504-1524, 2015. ,
Back to the basics: regular exercise matters in parkinson's disease: results from the National Parkinson Foundation QII registry study, Haute Autorité de Santé -Parkinson -Prise en charge non médicamenteuse des troubles moteurs, vol.20, pp.1221-1226, 2014. ,
Clinical Trials in Alzheimer's Disease Are Failing: What Can Be Done?, Translational Research & Clinical Interventions. 1 janv, vol.4, pp.195-214, 2018. ,
, , 2018.
,
Gantenerumab for the treatment of Alzheimer's disease, Expert Opin Biol Ther. août, vol.12, issue.8, pp.1077-86, 2012. ,
New Therapeutic Targets in Alzheimer's Disease, International Journal of Gerontology. 1 mars, vol.11, issue.1, pp.2-6, 2017. ,
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics, Science. 19 juill, vol.297, issue.5580, pp.353-359, 2002. ,
Immunotherapy for Alzheimer's disease, Immunotherapy. mai, vol.1, issue.3, pp.461-470, 2009. ,
The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review, Xconomy: Alzheon Files for IPO to Fund Studies of Amyloid Alzheimer's Drug, vol.24, 2012. ,
, , 2018.
,
,
, Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models, Proc Natl Acad Sci, vol.114, issue.10, pp.2699-704, 2017.
, Parkinson's Therapy Affitope Works by Triggering Immune Response to a Protein
, Parkinson's News Today, 2018.
,
Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: The example of Alzheimer's disease, Annales Pharmaceutiques Françaises. 1 juill, vol.71, issue.4, pp.225-258, 2013. ,
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders, Progress in Polymer Science. 1 août, vol.32, issue.8, pp.1054-82, 2007. ,
Poly(nResearch, mars, vol.1200, pp.159-68, 2008. ,
Development of poly(butylene succinate) microspheres for delivery of levodopa in the treatment of Parkinson's disease, J Biomed Mater Res Part B Appl Biomater. juill, vol.101, issue.5, pp.840-847, 2013. ,
Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery, Int J Pharm, vol.419, issue.1-2, pp.296-307, 2011. ,
Nanotechnology for neurodegenerative disorders, Nanomedicine: Nanotechnology, Biology and Medicine. 1 sept, vol.8, pp.51-59, 2012. ,
Neurotherapeutic applications of nanoparticles in Alzheimer's disease, Journal of Controlled Release. 10 juin, vol.152, issue.2, pp.208-239, 2011. ,
Gene mutation defends against Alzheimer's disease, Maladie neurodégénérative : mise en évidence de mutations génétiques impliquées, vol.487, 2012. ,
Pathogenic Lysosomal Depletion in Parkinson's Disease | Journal of Neuroscience ,
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration | PNAS ,
,
Credependent selection yields AAV variants for widespread gene transfer to the adult brain, Nat Biotechnol. févr, vol.34, issue.2, pp.204-213, 2016. ,
,
, PPAR?-coactivator-1? gene transfer reduces neuronal loss and amyloid-? generation by reducing ?-secretase in an Alzheimer's disease model, Proceedings of the National Academy of Sciences, vol.113, pp.12292-12299, 2016.
, Alzheimer's disease could be treated with gene therapy, suggests animal study | Imperial News | Imperial College London, 2018.
AbbVie and Voyager Therapeutics team up for Alzheimer's gene therapy, Chemical & Engineering News, vol.96, 2018. ,
Gene therapy for neurological disorders: progress and prospects, Nature Reviews Drug Discovery, issue.10, 2018. ,
,
,
Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease, Hum Gene Ther. avr, vol.23, issue.4, pp.377-81, 2012. ,
Neuroprotective effects of a triple GLP ,
, GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease, vol.1678, pp.64-74, 2018.
Diabetes mellitus and the risk of dementia: The Rotterdam Study, Neurology. 10 déc, vol.53, issue.9, pp.1937-1979, 1999. ,
How does brain insulin resistance develop in Alzheimer's disease?, Alzheimer's & Dementia. 1 févr, vol.10, issue.1, pp.26-32, 2014. ,
Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases. npj Parkinson's Disease. 23 janv, vol.3, p.4, 2017. ,
,
Peptides as Potential Therapeutics for Alzheimer's Disease. Molecules. 30 janv, vol.23, 2018. ,